Choosing the Right Regimen for Elderly Patients with Advanced RCC

Most clinical trials provide limited guidance on the appropriate treatment of patients seen in clinical practice. Particularly in oncology, participants in trials tend to be significantly younger and in substantially better health than the average patient. Renal cell carcinoma (RCC) provides a clear example of the challenge.

nCRC, Sequencing Offers Better Guidance than Staining When Results Differ

Chemotherapy has long been a component in the first-line treatment for advanced or metastatic colorectal cancer (mCRC). A number of studies in recent years indicate that a subset of patients with specific genetic mutations do not respond well to the recommended 5-fluorouracil-based regimens, such as FOLFOX (5-FU, oxaliplatin, and leucovorin) or FOLFIRI (5-FU, irinotecan, and leucovorin) alone or in combination with other agents.

Problems With DoD-to-VA Transition Program Intensified by Pandemic

Problems With DoD-to-VA Transition Program Intensified by Pandemic

Transitioning from active duty military service to civilian life is difficult at the best of times. The pandemic added a host of new challenges, highlighted existing problems with the transitioning process and widened the cracks through which those veterans who are most in need of support are in danger of falling.

Benzodiazepines Prescribed Long-Term for COPD/PTSD

SEATTLE — Symptoms of insomnia and anxiety are common among patients with chronic obstructive pulmonary disease, and that is especially the case among patients with comorbid mental health disorders such as posttraumatic stress disorder, according to a new study.

Debate Continues on Esketamine Efficacy and Safety for Depression Treatment

Debate Continues on Esketamine Efficacy and Safety for Depression Treatment

PHILADELPHIA—Is esketamine a revolutionary treatment for depression or just another moderately effective adjunctive medication with some potentially serious risks? The VA’s Medical Advisory Panel leaned toward the latter position when it decided in June to approve the use of esketamine on a nonformulary basis for individuals who have previously failed at least two trials of other antidepressants.